BABA
Alibaba Group Holding Limited
BABA's fundamentals are weak: its operating margin fell 10 points to 4.2% and free cash flow turned negative, though revenue grew 4.3%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
MRM
MEDIROM Healthcare Technologies Inc.
There isn't enough reported data to score MRM yet.
BABA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Healthy |
BABA's balance sheet is currently healthy, and its revenue is stable, but its profitability and cash flow are under pressure.
MRM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate MRM's fundamentals.
BABA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $69.66 | -26% |
| Fair | 20x | $86.59 | -8.2% |
| Current | 21x | $94.36 | — |
| Expensive | 26x | $115 | +22% |
Historical ranges are pointers, not guarantees.
BABA's PE is 21x, but its earnings don't support one, so it isn't a reliable read right now.
MRM PE Valuation
MRM has no meaningful PE right now: it lost money over the past year.
BABA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for BABA, with profitability improving. However, they disagree widely on these estimates.
MRM Forward outlook
There aren't enough analyst estimates for MRM to show an outlook.
BABA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $4.42 | -52% |
| Q1 2026 | $6.57 | -18% |
| Q4 2025 | $5.79 | -22% |
| Q3 2025 | $7.85 | +49% |
| Q2 2025 | $9.27 | +116% |
| Q1 2025 | $8.06 | +71% |
| Q4 2024 | $7.47 | +24% |
| Q3 2024 | $5.26 | -35% |
BABA's earnings per share have fallen from their peak: $4.42 over the past year, against $9.27 in mid-2025. Its recent earnings include one-off gains.
MRM Earnings Per Share
MRM and BABA do not have enough comparable growth data to identify a winner.
BABA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $40.2B | +8.3% |
| Q1 2026 | $36.5B | +2.9% |
| Q4 2025 | $42.7B | +1.7% |
| Q3 2025 | $37.2B | +4.8% |
| Q2 2025 | $37.2B | +1.8% |
| Q1 2025 | $35.5B | +6.6% |
| Q4 2024 | $42B | +7.6% |
| Q3 2024 | $35.5B | +5.2% |
BABA has the edge over MRM in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 7.2% | -6.9 points |
| Q1 2026 | -0.3% | -12 points |
| Q4 2025 | 7.1% | -7.6 points |
| Q3 2025 | 2.2% | -13 points |
| Q2 2025 | 14% | -0.7 points |
| Q1 2025 | 12% | +5.4 points |
| Q4 2024 | 15% | +6.1 points |
| Q3 2024 | 15% | 0 points |
BABA's operating margin was 7.2% last quarter, down 6.9 points from the same quarter a year ago.
MRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $3.8M | -87% |
| Q2 2025 | $20.3M | -6.7% |
| Q4 2024 | $30.2M | +35% |
| Q2 2024 | $21.8M | +7.2% |
| Q4 2023 | $22.5M | -5.8% |
| Q2 2023 | $20.3M | +106% |
| Q4 2022 | $23.9M | +132% |
| Q2 2022 | $9.9M | -26% |
MRM's revenue has held roughly level: $4M last quarter, down 83% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 12% | +14 points |
| Q2 2025 | -28% | -19 points |
| Q4 2024 | 13% | +6.2 points |
| Q2 2024 | -18% | -13 points |
| Q4 2023 | -2.3% | +12 points |
| Q2 2023 | -9.6% | +15 points |
| Q4 2022 | 6.6% | +60 points |
| Q2 2022 | -4.9% | +59 points |
MRM's operating margin was 12% last quarter, up 14 points from the same quarter a year ago.
BABA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.7B | -$4.1B |
| Q1 2026 | -$2.7B | +$1.5B |
| Q4 2025 | $1B | -90% |
| Q3 2025 | -$3.2B | -254% |
| Q2 2025 | -$2.7B | -182% |
| Q1 2025 | -$4.2B | -12231% |
| Q4 2024 | $10.4B | -4.8% |
| Q3 2024 | $2.1B | -62% |
BABA's free cash flow has turned negative after years in the green: −$11.6B over the past year.
MRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2025 | -$2.3M | +$2.7M |
| Q4 2024 | -$6.8M | -$6.2M |
| Q2 2024 | -$5M | -$865.8K |
| Q4 2023 | -$634.9K | +$2.4M |
| Q2 2023 | -$4.2M | -$3.2M |
| Q4 2022 | -$3M | -$2.2M |
| Q2 2022 | -$1M | +$197.1K |
| Q4 2021 | -$825K | -4728% |
MRM has burned cash in most quarters: −$15M over the past year, against −$9M the year before.
BABA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +11.1M shares |
| 1 year | +0.9% | +21.4M shares |
| 3 years | -6.2% | -161M shares |
| 5 years | -12% | -339M shares |
| Available history | -8.4% | -221M shares |
BABA has the edge over MRM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $269.8M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BABA spent $270M buying back its own shares over the past year, after none the year before.
MRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +3K shares |
| 1 year | +45% | +2.5M shares |
| 3 years | +85% | +3.6M shares |
MRM has 8M diluted shares, up 45% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | — |
| Q4 2023 | — |
| Q2 2023 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q2 2021 | — |
BABA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | -0.2x | Net Cash |
BABA's net debt is less than a year of its operating earnings (EBITDA).
MRM Net Leverage
MRM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BABA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 12.7 | Oversold |
BABA's weekly RSI is 38 (neutral) and its Stochastic is 13 (oversold).
MRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.1 | Oversold |
| Stochastic | 6.2 | Oversold |
MRM's weekly RSI is 22 (oversold) and its Stochastic is 6 (oversold).
BABA PE vs Consumer Cyclical Sector
| Metric | BABA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 18x | 19% above |
| PE % | 60 | 47 | 13 pts above |
BABA is trading at 21x earnings, a 19% premium to the Consumer Cyclical sector's median of 18x, though its earnings don't support one.
MRM PE vs Consumer Cyclical Sector
| Metric | MRM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
MRM has no meaningful PE right now: it lost money over the past year.
BABA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.7 | 9.9% below |
| 20 week MA | $111.1 | 15% below |
| 50 week MA | $128.0 | 26% below |
| 100 week MA | $127.7 | 26% below |
| 200 week MA | $106.4 | 11% below |
BABA is in a downtrend: it's below all five of its weekly moving averages, and 11% below its 200-week average.
MRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.43 | 35% below |
| 20 week MA | $0.74 | 62% below |
| 50 week MA | $1.15 | 76% below |
| 100 week MA | $1.28 | 78% below |
| 200 week MA | $3.21 | 91% below |
MRM is in a downtrend: it's below all five of its weekly moving averages, and 91% below its 200-week average.
BABA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $215.5 | $222.0 | +3% |
| 2021 | $222.0 | $118.7 | -47% |
| 2022 | $118.7 | $85.7 | -28% |
| 2023 | $85.7 | $77.5 | -9.5% |
| 2024 | $77.5 | $85.1 | +9.7% |
| 2025 | $85.1 | $152.2 | +79% |
| 2026 YTD | $152.2 | $94.4 | -38% |
BABA has the edge over MRM on returns for 2026, with the stronger performance.
MRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $14.4 | $6.26 | -57% |
| 2022 | $6.26 | $5.58 | -11% |
| 2023 | $5.58 | $5.72 | +2.5% |
| 2024 | $5.72 | $1.05 | -82% |
| 2025 | $1.05 | $2.21 | +110% |
| 2026 YTD | $2.21 | $0.28 | -87% |
MRM's yearly returns have swung widely, from +110% in 2025 to −82% in 2024. It's down 87% so far in 2026.